| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial |
| Creator | Jacot et al. |
| Author | William Jacot |
| Author | Paul Cottu |
| Author | Frederique Berger |
| Author | Coraline Dubot |
| Author | Laurence Venat-Bouvet |
| Author | Alain Lortholary |
| Author | Hugues Bourgeois |
| Author | Marc Bollet |
| Author | Elisabeth Luporsi |
| Author | Marie-Paule Sablin |
| Author | Etienne Brain |
| Author | Souhir Neffati |
| Author | Jean-Yves Pierga |
| Abstract | BACKGROUND: In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. METHODS: Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ??2 prior lines of chemotherapy and measurable disease. CTC with a HER2/CEP17 ratio of ??2.2 by fluorescent in situ hybridization (CellSearch) were considered to be HER2-amplified (HER2amp). Patients with ??1 HER2amp CTC were eligible for the treatment phase (T-DM1 monotherapy). The primary endpoint was the overall response rate. RESULTS: In 154 screened patients, ??1 and ??5 CTC/7.5?ml of blood were detected in N?=?118 (78.7%) and N?=?86 (57.3%) patients, respectively. ?1 HER2amp CTC was found in 14 patients (9.1% of patients with ??1 CTC/7.5?ml). Among 11 patients treated with T-DM1, one achieved a confirmed partial response. Four patients had a stable disease as best response. Median PFS was 4.8?months while median OS was 9.5?months. CONCLUSIONS: CTC with HER2 amplification can be detected in a limited subset of HER2-negative MBC patients. Treatment with T-DM1 achieved a partial response in only one patient. TRIAL REGISTRATION: NCT01975142, Registered 03 November 2013. |
| Publication | Breast cancer research: BCR |
| Volume | 21 |
| Issue | 1 |
| Pages | 121 |
| Date | 11 14, 2019 |
| Journal Abbr | Breast Cancer Res. |
| Language | eng |
| DOI | 10.1186/s13058-019-1215-z |
| ISSN | 1465-542X |
| Short Title | Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 31727113 PMCID: PMC6854749 |
| Tags | Circulating tumor cells, first, first-last-corresponding, HER2, original, Trastuzumab-emtansine |
| Date Added | 2020/01/21 - 10:48:19 |
| Date Modified | 2022/08/01 - 16:14:30 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
